Anesthesia Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Cisapride pharmacological and physiological characteristic(s):
1. 5-HT₄ agonist
2. Weak 5-HT₃ antagonist
3. Both
4. Neither
Cisapride:
1. Exhibits prokinetic properties but this agent is not commonly available in the United States because of serious side effects.
2. Metabolized by the liver utilizing mainly the CYP3A4 isoform of the cytochrome P450 microsomal metabolizing system.
3. Both
4. Neither
Cardiac arrhythmias associated with cisapride administration is likely a consequence of drug-induced prolongation of the QT interval.
1. True
2. False
Limited-access program(s) for patients to receive cisapride:
1. GERD
2. Refractory severe chronic constipation
3. Both
4. Neither
Limited-access program(s) for patients to receive cisapride:
1. Intestinal pseudoobstruction
2. Gastroparesis
3. Both
4. Neither
Cisapride contraindication(s):
1. Patients with prolonged QT intervals
2. Patients with renal failure
3. Patients with ischemic heart disease
4. A & B
5. B & C
6. A & C
7. A, B & C
Cisapride contraindication(s):
1. Patients with congestive heart failure history
2. Patients with respiratory failure
3. Unresolved electrolyte abnormalities
4. A & B
5. B & C
6. A & C
7. A, B & C
Prucalopride (Resolor):
1. 5-HT₄ receptor agonist
2. Increases cholinergic neurotransmission
3. Both
4. Neither
Prucalopride administration increases colonic an oral-cecal transit while not altering gastric emptying in normal subjects.
1. True
2. False
Classified as a 5-HT₄ partial agonist:
1. Alosetron
2. Tegaserod
3. Prucalopride
4. Metoclopramide

Anesthesia Pharmacology: Gastrointestinal Pharmacology Practice Questions